{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T07:26:58Z","timestamp":1780730818219,"version":"3.54.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T00:00:00Z","timestamp":1508716800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s41669-017-0058-8","type":"journal-article","created":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T17:37:48Z","timestamp":1508780268000},"page":"233-239","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Review of Clinical and Economic Evaluations Applied to Psychotropic Therapies Used in the Treatment of Schizophrenia in Argentina"],"prefix":"10.1007","volume":"2","author":[{"given":"Gisela Paula","family":"Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nebel Silvana","family":"Moscoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Pablo","family":"Lago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,23]]},"reference":[{"key":"58_CR1","unstructured":"WHO. Schizophrenia: fact sheet N\u00b0397. Media Centre. 2016. https:\/\/goo.gl\/g0ARGP ."},{"key":"58_CR2","first-page":"008016","volume":"5","author":"S Leucht","year":"2012","unstructured":"Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2012;5:008016.","journal-title":"Cochrane Database Syst Rev"},{"key":"58_CR3","unstructured":"Oliva-Moreno J, Gonz\u00e1lez A, Aranda I, Hidalgo A, Vilaplana C. Cuidados informales asociados a la limitaci\u00f3n de la autonom\u00eda en personas con esquizofrenia. En: Bobes J, Saiz J, editors. Impacto social de la esquizofrenia, vol. 1, no. 1. Barcelona: Glosa. pp. 105\u201329."},{"key":"58_CR4","volume-title":"Methods for the development of NICE public health guidance","author":"National Institute for Clinical Excellence","year":"2006","unstructured":"National Institute for Clinical Excellence. Methods for the development of NICE public health guidance. London: NICE; 2006."},{"issue":"1","key":"58_CR5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.rpsm.2016.09.001","volume":"10","author":"B Crespo-Facorro","year":"2017","unstructured":"Crespo-Facorro B, Bernardo M, Argimon JM, Arrojo M, Bravo-Ortiz MF, Cabrera-Cifuentes A, et al. Eficacia, eficiencia y efectividad en el tratamiento multidimensional de la esquizofrenia: proyecto Rethinking. Revista de Psiquiatr\u00eda y Salud Mental. 2017;10(1):4\u201320.","journal-title":"Revista de Psiquiatr\u00eda y Salud Mental."},{"key":"58_CR6","unstructured":"World Health Organization. WHO model list of essential medicines: 18th list. April 2013. https:\/\/goo.gl\/Ekj8yc ."},{"issue":"6","key":"58_CR7","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1590\/S0102-311X2007000600002","volume":"23","author":"L Ortiz-Hern\u00e1ndez","year":"2007","unstructured":"Ortiz-Hern\u00e1ndez L, L\u00f3pez-Moreno S, Borges G. Desigualdad socioecon\u00f3mica y salud mental: revisi\u00f3n de la literatura latinoamericana. Cadernos de sa\u00fade p\u00fablica. 2007;23(6):1255\u201372.","journal-title":"Cadernos de sa\u00fade p\u00fablica"},{"issue":"119","key":"58_CR8","first-page":"11","volume":"26","author":"EA Leiderman","year":"2015","unstructured":"Leiderman EA, Lorenzo L. Prescription patterns in the treatment of schizophrenia [in Spanish]. Vertex (Buenos Aires, Argentina). 2015;26(119):11\u20136.","journal-title":"Vertex (Buenos Aires, Argentina)"},{"key":"58_CR9","unstructured":"Ministerio de Salud de la Naci\u00f3n (MSN). Primer Registro Centralizado de patolog\u00edas cognitivas en Argentina (ReDeCAr). 2011. https:\/\/goo.gl\/5r6Hoy ."},{"key":"58_CR10","unstructured":"Cornejo-Le\u00f3n F, Dragotto M, Ramos G, Klein R, Vernimmen P, Corral RM. Tratamiento farmacol\u00f3gico en pacientes con esquizofrenia. Alcmeon. 2006;13(3):20\u20139."},{"key":"58_CR11","unstructured":"Ministerio de Salud de la Naci\u00f3n (MSN), Lineamientos para la atenci\u00f3n de la urgencia en Salud Mental. Red de servicios de Salud Mental con base en la comunidad. 2013. https:\/\/goo.gl\/77ttzk ."},{"key":"58_CR12","unstructured":"Ag\u00e8ncia d\u2019Avaluaci\u00f3 de Tecnologia i Recerca M\u00e8diques de Catalu\u00f1a (AATRMC). Gu\u00eda de Pr\u00e1ctica Cl\u00ednica sobre la Esquizofrenia y el Trastorno Psic\u00f3tico Incipiente. GuiaSalud. 2009. https:\/\/goo.gl\/9NjZuO ."},{"key":"58_CR13","first-page":"361","volume":"9","author":"SA Alvano","year":"2000","unstructured":"Alvano SA. Pautas de tratamiento y manejo cl\u00ednico. ALCMEON Revista Argentina de Cl\u00ednica Neuropsiqui\u00e1trica. 2000;9:361\u20136.","journal-title":"ALCMEON Revista Argentina de Cl\u00ednica Neuropsiqui\u00e1trica."},{"issue":"1","key":"58_CR14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1176\/foc.2.1.175","volume":"2","author":"NR Schooler","year":"2004","unstructured":"Schooler NR. Maintenance medication for schizophrenia: strategies for dose reduction. Focus. 2004;2(1):175\u201386. doi: 10.1176\/foc.2.1.175 .","journal-title":"Focus."},{"issue":"5","key":"58_CR15","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/2045125314540297","volume":"4","author":"S Brissos","year":"2014","unstructured":"Brissos S, Veguilla MR, Taylor D, Balanz\u00e1-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 2014;4(5):198\u2013219.","journal-title":"Ther Adv Psychopharmacol."},{"issue":"5","key":"58_CR16","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/schbul\/sbt096","volume":"39","author":"S Sampson","year":"2013","unstructured":"Sampson S, Joshi K, Mansour M, Adams CE. Intermittent drug techniques for schizophrenia. Schizophr Bull. 2013;39(5):960\u20131.","journal-title":"Schizophr Bull"},{"issue":"1","key":"58_CR17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00148365-200806010-00004","volume":"6","author":"JM Olivares","year":"2008","unstructured":"Olivares JM, Rodriguez-Martinez A, Bur\u00f3n JA, Alonso-Escolano D, Rodriguez-Morales A. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia. Appl Health Econ Health Policy. 2008;6(1):41\u201353.","journal-title":"Appl Health Econ Health Policy."},{"issue":"3","key":"58_CR18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/j.2051-5545.2009.tb00233.x","volume":"8","author":"RD Alarc\u00f3n","year":"2009","unstructured":"Alarc\u00f3n RD. Culture, cultural factors and psychiatric diagnosis: review and projections. World Psychiatry. 2009;8(3):131\u20139.","journal-title":"World Psychiatry."},{"issue":"1","key":"58_CR19","first-page":"269","volume":"4","author":"J Jin","year":"2008","unstructured":"Jin J, Sklar GE, Oh VMS, Li SC. Factors affecting therapeutic compliance: a review from the patient\u2019s perspective. Ther Clin Risk Manag. 2008;4(1):269.","journal-title":"Ther Clin Risk Manag"},{"issue":"6","key":"58_CR20","doi-asserted-by":"crossref","first-page":"568","DOI":"10.4088\/JCP.12r08167","volume":"74","author":"NY Kirson","year":"2013","unstructured":"Kirson NY, Weiden PJ, Yermakov S, Huang W, Samuelson T, Offord SJ, Wong SJ. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry. 2013;74(6):568\u201375.","journal-title":"J Clin Psychiatry"},{"key":"58_CR21","unstructured":"Quraishi SN, David A, Brasil MA, Alheira FV. Depot haloperidol decanoate for schizophrenia. Cochrane Database Syst Rev. 2011;(1):24\u201340."},{"key":"58_CR22","doi-asserted-by":"crossref","unstructured":"Dold M, Samara MT, Li C, Tardy M, Leucht S. Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. Cochrane Database Syst Rev. 2015;(1):152\u201377.","DOI":"10.1002\/14651858.CD009831.pub2"},{"key":"58_CR23","doi-asserted-by":"crossref","unstructured":"Tardy M, Huhn M, Kissling W, Engel RR, Leucht S. Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2014;(7):CD009268.","DOI":"10.1002\/14651858.CD009268.pub2"},{"key":"58_CR24","doi-asserted-by":"crossref","unstructured":"Dold M, Li C, Tardy M, Khorsand V, Gillies D, Leucht S. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev. 2012;(11):95\u2013116.","DOI":"10.1002\/14651858.CD006391.pub2"},{"key":"58_CR25","doi-asserted-by":"crossref","unstructured":"Leucht C, Kitzmantel M, Kane J, Leucht S, Chua WLLC. Haloperidol versus chlorpromazine for schizophrenia. The Cochrane Library. 2008. https:\/\/goo.gl\/mIqm72 .","DOI":"10.1002\/14651858.CD004278.pub2"},{"issue":"3","key":"58_CR26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1586\/erp.12.23","volume":"12","author":"P Chue","year":"2012","unstructured":"Chue P, Chue J. The cost\u2013effectiveness of risperidone long-acting injection in the treatment of schizophrenia. Expert Rev Pharmacoecon Outcomes Res. 2012;12(3):259\u201369.","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"issue":"6","key":"58_CR27","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1176\/appi.ajp.2011.10081224","volume":"168","author":"J Tiihonen","year":"2011","unstructured":"Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603\u20139.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"58_CR28","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4088\/JCP.11m07070","volume":"73","author":"PG Barnett","year":"2012","unstructured":"Barnett PG, Scott JY, Krystal JH, Rosenheck RA. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. J Clin Psychiatry. 2012;73(5):696\u2013702.","journal-title":"J Clin Psychiatry"},{"key":"58_CR29","doi-asserted-by":"crossref","unstructured":"Sampson S, Hosalli P, Furtado VA, Davis JM. Risperidone (depot) for schizophrenia. The Cochrane Library. Cochrane Database Syst Rev. 2016;(4):89\u2013120.","DOI":"10.1002\/14651858.CD004161.pub2"},{"issue":"3","key":"58_CR30","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/schbul\/sbu128","volume":"41","author":"J Nielsen","year":"2015","unstructured":"Nielsen J, Jensen SO, Friis RB, Valentin JB, Correll CU. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study. Schizophr Bull. 2015;41(3):627\u201336.","journal-title":"Schizophr Bull"},{"issue":"2","key":"58_CR31","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/2010105815618673","volume":"25","author":"AWS Chee","year":"2016","unstructured":"Chee AWS, Abidin EB, Verma SK. Short term effectiveness of haloperidol versus risperidone in first-episode schizophrenia. Proc Singapore Healthc. 2016;25(2):72\u20139.","journal-title":"Proc Singapore Healthc."},{"issue":"2","key":"58_CR32","first-page":"152","volume":"4","author":"SM Tamrakar","year":"2006","unstructured":"Tamrakar SM, Nepal MK, Koirala NR, Sharma VD, Gurung CK, Adhikari SR. An open, randomized, comparative study of efficacy and safety of risperidone and haloperidol in schizophrenia. Kathmandu Univ Med J. 2006;4(2):152\u201360.","journal-title":"Kathmandu Univ Med J."},{"issue":"2","key":"58_CR33","first-page":"55","volume":"24","author":"SP Ahmed","year":"2007","unstructured":"Ahmed SP, Siddiq AFSHAN, Baig SG, Khan RA. Comparative efficacy of haloperidol and risperidone: a review. Pak J Pharmacol. 2007;24(2):55\u201364.","journal-title":"Pak J Pharmacol"},{"key":"58_CR34","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1176\/appi.ps.52.7.911","volume":"52","author":"MA Escamilla","year":"2001","unstructured":"Escamilla MA. Diagnosis and treatment of mood disorders that co-occur with schizophrenia. Psychiatr Serv. 2001;52:911\u20139.","journal-title":"Psychiatr Serv"},{"key":"58_CR35","doi-asserted-by":"crossref","first-page":"S264","DOI":"10.1016\/S0924-977X(01)80319-9","volume":"11","author":"RA Emsley","year":"2001","unstructured":"Emsley RA, Jones AM. Treatment of depressive symptoms in partially refractory schizophrenia: efficacy of quetiapine versus haloperidol. Eur Neuropsychopharmacol. 2001;11:S264\u20135.","journal-title":"Eur Neuropsychopharmacol"},{"key":"58_CR36","doi-asserted-by":"crossref","unstructured":"Furtado VA, Srihari V, Kumar A. Atypical antipsychotics for people with both schizophrenia and depression. The Cochrane Library. 2008. https:\/\/goo.gl\/gqkVIv .","DOI":"10.1002\/14651858.CD005377.pub2"},{"issue":"1","key":"58_CR37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/00019053-200523001-00004","volume":"23","author":"D Graeve De","year":"2005","unstructured":"De Graeve D, Smet A, Mehnert A, Caleo S, Miadi-Fargier H, Mosqueda GJ, et al. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. Pharmacoeconomics. 2005;23(1):35\u201347.","journal-title":"Pharmacoeconomics."},{"issue":"4","key":"58_CR38","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1440-1819.2005.01390.x","volume":"59","author":"YK Yang","year":"2005","unstructured":"Yang YK, Tarn YH, Wang TY, Liu CY, Laio YC, Chou YH, et al. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs. Psychiatry Clin Neurosci. 2005;59(4):385\u201394.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"5","key":"58_CR39","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/11536180-000000000-00000","volume":"8","author":"M Hensen","year":"2010","unstructured":"Hensen M, Heeg B, L\u00f6thgren M, van Hout B. Cost effectiveness of long-acting risperidone in Sweden. Appl Health Econ Health Policy. 2010;8(5):327\u201341.","journal-title":"Appl Health Econ Health Policy."},{"key":"58_CR40","doi-asserted-by":"crossref","unstructured":"Jayaram MB, Hosalli P, Stroup TS. Risperidone versus olanzapine for schizophrenia. Cochrane Database Syst Rev. 2006;(2):50\u201399.","DOI":"10.1002\/14651858.CD005237.pub2"},{"issue":"7595","key":"58_CR41","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/bmj.39148.668160.80","volume":"334","author":"P Byrne","year":"2007","unstructured":"Byrne P. Managing the acute psychotic episode. BMJ Br Med J. 2007;334(7595):686.","journal-title":"BMJ Br Med J."},{"issue":"9657","key":"58_CR42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","volume":"373","author":"S Leucht","year":"2009","unstructured":"Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31\u201341.","journal-title":"Lancet"},{"issue":"5","key":"58_CR43","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/schbul\/sbn019","volume":"35","author":"J Parks","year":"2008","unstructured":"Parks J, Radke A, Parker G, Foti ME, Eilers R, Diamond M, Svendsen D, Tandon R. Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment. Schizophr Bull. 2008;35(5):931\u20136.","journal-title":"Schizophr Bull"},{"issue":"9896","key":"58_CR44","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, \u00d6rey D, Richter F, Samara M, Barbui C, Engel R, Geddes JR, Kissling W, Paul Stapf M, L\u00e4ssig B, Salanti G, Davis J. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951\u201362.","journal-title":"Lancet"},{"key":"58_CR45","volume-title":"Psychosis and schizophrenia in adults","author":"National Collaborating Centre for Mental Health UK","year":"2014","unstructured":"National Collaborating Centre for Mental Health UK. Psychosis and schizophrenia in adults. London: National Collaborating Centre for Mental Health; 2014."},{"issue":"1","key":"58_CR46","first-page":"251","volume":"20","author":"A Tisera","year":"2013","unstructured":"Tisera A, L\u00e9ale H, Lohigorry J, Pekarek AL, Joskowicz A. Salud Mental y desinstitucionalizaci\u00f3n: resistencias y obst\u00e1culos en los procesos de externaci\u00f3n en un hospital monovalente de la zona sur de la Ciudad de Buenos Aires. Anuario de investigaciones. 2013;20(1):251\u20138.","journal-title":"Anuario de investigaciones"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s41669-017-0058-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-017-0058-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-017-0058-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T21:36:42Z","timestamp":1570225002000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s41669-017-0058-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,23]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["58"],"URL":"https:\/\/doi.org\/10.1007\/s41669-017-0058-8","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,23]]}}}